• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不同 CT 增强量化方法在预测术前手术治疗后胰腺癌复发中的表现。

Performance of different CT enhancement quantification methods as predictors of pancreatic cancer recurrence after upfront surgery.

机构信息

Clinic for Diagnostic and Interventional Radiology, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.

Department of Neuroradiology, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.

出版信息

Sci Rep. 2024 Aug 26;14(1):19783. doi: 10.1038/s41598-024-70441-3.

DOI:10.1038/s41598-024-70441-3
PMID:39187515
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11347575/
Abstract

The prognosis of pancreatic cancer (PDAC) after tumor resection remains poor, mostly due to a high but variable risk of recurrence. A promising tool for improved prognostication is the quantification of CT tumor enhancement. For this, various enhancement formulas have been used in previous studies. However, a systematic comparison of these formulas is lacking. In the present study, we applied twenty-three previously published CT enhancement formulas to our cohort of 92 PDAC patients who underwent upfront surgery. We identified seven formulas that could reliably predict tumor recurrence. Using these formulas, weak tumor enhancement was associated with tumor recurrence at one and two years after surgery (p ≤ 0.030). Enhancement was inversely associated with adverse clinicopathological features. Low enhancement values were predictive of a high recurrence risk (Hazard Ratio ≥ 1.659, p ≤ 0.028, Cox regression) and a short time to recurrence (TTR) (p ≤ 0.027, log-rank test). Some formulas were independent predictors of TTR in multivariate models. Strikingly, almost all of the best-performing formulas measure solely tumor tissue, suggesting that normalization to non-tumor structures might be unnecessary. Among the top performers were also the absolute arterial/portal venous tumor attenuation values. These can be easily implemented in clinical practice for better recurrence prediction, thus potentially improving patient management.

摘要

胰腺癌(PDAC)切除术后的预后仍然较差,主要是因为复发风险高但变化较大。一种有前途的改善预后的工具是 CT 肿瘤增强的定量。为此,在以前的研究中使用了各种增强公式。然而,这些公式之间缺乏系统的比较。在本研究中,我们将 23 种以前发表的 CT 增强公式应用于我们的 92 名接受直接手术的 PDAC 患者队列。我们确定了七种可以可靠预测肿瘤复发的公式。使用这些公式,术后 1 年和 2 年肿瘤增强弱与肿瘤复发相关(p≤0.030)。增强与不良临床病理特征呈负相关。低增强值预示着高复发风险(危险比≥1.659,p≤0.028,Cox 回归)和复发时间短(TTR)(p≤0.027,对数秩检验)。一些公式在多变量模型中是 TTR 的独立预测因子。值得注意的是,表现最好的公式几乎都只测量肿瘤组织,这表明对非肿瘤结构进行归一化可能是不必要的。表现最好的公式中还包括绝对动脉/门静脉肿瘤衰减值。这些可以很容易地在临床实践中实施,以更好地预测复发,从而有可能改善患者的管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1cf/11347575/7929a0602a2e/41598_2024_70441_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1cf/11347575/1f9643308640/41598_2024_70441_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1cf/11347575/85d4917a33d3/41598_2024_70441_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1cf/11347575/7929a0602a2e/41598_2024_70441_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1cf/11347575/1f9643308640/41598_2024_70441_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1cf/11347575/85d4917a33d3/41598_2024_70441_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1cf/11347575/7929a0602a2e/41598_2024_70441_Fig3_HTML.jpg

相似文献

1
Performance of different CT enhancement quantification methods as predictors of pancreatic cancer recurrence after upfront surgery.不同 CT 增强量化方法在预测术前手术治疗后胰腺癌复发中的表现。
Sci Rep. 2024 Aug 26;14(1):19783. doi: 10.1038/s41598-024-70441-3.
2
Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of a Risk Score.基于胰腺 CT 预测可切除胰腺导管腺癌患者根治性手术后复发风险的评分系统:开发与验证。
Radiology. 2020 Sep;296(3):541-551. doi: 10.1148/radiol.2020200281. Epub 2020 Jul 14.
3
Predicting Recurrence-Free Survival After Upfront Surgery in Resectable Pancreatic Ductal Adenocarcinoma: A Preoperative Risk Score Based on CA 19-9, CT, and F-FDG PET/CT.术前基于 CA 19-9、CT 和 F-FDG PET/CT 的评分系统预测可切除胰腺导管腺癌根治性手术后无复发生存率。
Korean J Radiol. 2024 Jul;25(7):644-655. doi: 10.3348/kjr.2023.1235.
4
A predictive model for recurrence after upfront surgery in patients with resectable pancreatic ductal adenocarcinoma (PDAC) by using preoperative clinical data and CT characteristics.术前临床数据和 CT 特征预测可切除胰腺导管腺癌(PDAC)患者 upfront 手术后复发的模型。
BMC Med Imaging. 2022 Jul 3;22(1):116. doi: 10.1186/s12880-022-00823-4.
5
Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor.血管生成和肿瘤大小是影响胰腺神经内分泌瘤切除术后复发的重要预测因素。
Ann Surg Oncol. 2017 Aug;24(8):2363-2370. doi: 10.1245/s10434-017-5823-5. Epub 2017 Mar 7.
6
Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma.增强 CT 延迟期的视觉增强模式是 IV 期胰腺导管腺癌的独立预后因素。
Pancreatology. 2020 Sep;20(6):1155-1163. doi: 10.1016/j.pan.2020.07.009. Epub 2020 Jul 28.
7
Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.应用增强 CT 和 CA19-9 对 R0 切除术后胰腺导管腺癌患者无病生存的术前预测。
Eur Radiol. 2024 Jan;34(1):509-524. doi: 10.1007/s00330-023-09980-8. Epub 2023 Jul 28.
8
Prognostic value of CT findings to predict survival outcomes in patients with pancreatic neuroendocrine neoplasms: a single institutional study of 161 patients.CT检查结果对预测胰腺神经内分泌肿瘤患者生存结局的预后价值:一项针对161例患者的单机构研究
Eur Radiol. 2016 May;26(5):1320-9. doi: 10.1007/s00330-015-3943-5. Epub 2015 Aug 8.
9
Dual-Energy Perfusion-CT in Recurrent Pancreatic Cancer - Preliminary Results.双能量灌注CT在复发性胰腺癌中的应用——初步结果
Rofo. 2016 Jun;188(6):559-65. doi: 10.1055/s-0042-105765. Epub 2016 May 25.
10
Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.根治性手术切除后可切除性胰腺导管腺癌患者早期复发的术前危险因素。
Hepatobiliary Pancreat Dis Int. 2018 Oct;17(5):450-455. doi: 10.1016/j.hbpd.2018.09.003. Epub 2018 Sep 7.

引用本文的文献

1
CT-based multi-regional radiomics model for predicting contrast medium extravasation in patients with tumors: A case-control study.基于CT的多区域放射组学模型预测肿瘤患者造影剂外渗:一项病例对照研究。
PLoS One. 2025 Mar 10;20(3):e0314601. doi: 10.1371/journal.pone.0314601. eCollection 2025.

本文引用的文献

1
Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within Cohorts design.使用基于复发监测策略的 RADAR-PANC 对胰腺导管腺癌切除术后的疾病复发进行检测:一项按照队列内试验设计的国际随机对照试验方案。
Trials. 2024 Jun 20;25(1):401. doi: 10.1186/s13063-024-08223-5.
2
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
3
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
胰腺癌:欧洲肿瘤内科学会临床实践指南之诊断、治疗及随访
Ann Oncol. 2023 Nov;34(11):987-1002. doi: 10.1016/j.annonc.2023.08.009. Epub 2023 Sep 9.
4
Rim Enhancement and Peripancreatic Fat Stranding in Preoperative MDCT as Predictors for Occult Metastasis in PDAC Patients.术前 MDCT 中胰腺边缘强化和胰周脂肪条索征作为预测 PDAC 患者隐匿性转移的指标。
Acad Radiol. 2023 Dec;30(12):2954-2961. doi: 10.1016/j.acra.2023.03.007. Epub 2023 Apr 4.
5
A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer.范式转变:可明显切除的胰腺癌的新辅助治疗。
Ann Surg Oncol. 2023 Jun;30(6):3427-3436. doi: 10.1245/s10434-023-13281-1. Epub 2023 Mar 4.
6
Pancreatic Cancer: A Review of Current Treatment and Novel Therapies.胰腺癌:当前治疗方法与新型疗法综述
J Invest Surg. 2023 Dec 31;36(1):2129884. doi: 10.1080/08941939.2022.2129884. Epub 2022 Oct 3.
7
Prognostic value of preoperative enhanced computed tomography as a quantitative imaging biomarker in pancreatic cancer.术前增强 CT 作为一种定量成像生物标志物对胰腺癌的预后价值。
World J Gastroenterol. 2022 Jun 14;28(22):2468-2481. doi: 10.3748/wjg.v28.i22.2468.
8
Deep Learning for Fully Automated Prediction of Overall Survival in Patients Undergoing Resection for Pancreatic Cancer: A Retrospective Multicenter Study.深度学习在胰头癌切除术患者总生存预测中的完全自动化应用:一项回顾性多中心研究。
Ann Surg. 2023 Jul 1;278(1):e68-e79. doi: 10.1097/SLA.0000000000005465. Epub 2022 Jul 4.
9
Resection of Recurrent Pancreatic Cancer: Who Can Benefit?复发性胰腺癌的切除术:谁能从中获益?
Visc Med. 2022 Feb;38(1):42-48. doi: 10.1159/000519754. Epub 2021 Nov 11.
10
Treatment and survival of patients with pancreatic ductal adenocarcinoma: 15-year national cohort.胰腺导管腺癌患者的治疗和生存情况:15 年全国队列研究。
BJS Open. 2022 Mar 8;6(2). doi: 10.1093/bjsopen/zrac004.